Search results “Renal cell cancer for patients”
Renal cell carcinoma - causes, symptoms, diagnosis, treatment, pathology
What is Renal Cell Carcinoma? It form from epithelial cells in the proximal convoluted tubule of the kidney. Find more videos at http://osms.it/more. Study better with Osmosis Prime. Retain more of what you’re learning, gain a deeper understanding of key concepts, and feel more prepared for your courses and exams. Sign up for a free trial at http://osms.it/more. Subscribe to our Youtube channel at http://osms.it/subscribe. Get early access to our upcoming video releases, practice questions, giveaways and more when you follow us on social: Facebook: http://osms.it/facebook Twitter: http://osms.it/twitter Instagram: http://osms.it/instagram Thank you to our Patreon supporters: Alex Wright Omar Berrios Osmosis's Vision: Empowering the world’s caregivers with the best learning experience possible.
Views: 88787 Osmosis
Renal Cell Carcinoma
(Visit: http://www.uctv.tv/) In the United States, there are over 60,000 new diagnoses and nearly 14,000 deaths from kidney cancer each year. Dr. Won Kim reviews the epidemiology of kidney cancer (including established risk factors), the biology and pathophysiology of kidney cancer, treatment options for localized disease, and the role of systemic therapy in the treatment of advanced, metastatic disease. He also discusses the current and future role of immunotherapy in kidney cancer. Recorded on 07/15/2014. Series: "UCSF Osher Center for Integrative Medicine presents Mini Medical School for the Public" [9/2014] [Health and Medicine] [Show ID: 28502]
Renal Cell Carcinoma - causes, symptoms and treatment
Renal cell carcinoma (RCC) is also called hypernephroma, renal adenocarcinoma, or renal or kidney cancer. It’s the most common kind of kidney cancer found in adults. The kidneys are organs in your body that help get rid of waste, while also regulating fluid balance. Subscribe my channel: https://www.youtube.com/channel/UCjPGXgOH-anpsvLMiw8NYdA Follow us: https://plus.google.com/u/0/b/118041852373056007310/118041852373056007310 https://web.facebook.com/Health-Tips-Page-1724798314435434/ https://twitter.com/?lang=en Other videos: https://www.youtube.com/watch?v=1HW0r0QGSvk https://www.youtube.com/watch?v=iMuesRzj22M https://www.youtube.com/watch?v=hKNqwbfxzyc https://www.youtube.com/watch?v=9KySzN3unQU Symptoms of Renal cell carcinoma. Early on, renal cell carcinoma doesn’t usually cause any sign. As the disease gets more advance, you might have warning signs like: A lump on your side, belly, or lower back. Blood in your pee. Low back pain on one side. Losing weight for no clear reason. Lose of appetite. Fever. Feeling tired. Not enough red blood cells (anemia). Night sweats. High levels of calcium in your blood. High blood pressure. Causes of Renal cell carcinoma. The exact cause of renal cell carcinoma is not known. Scientist know that most kidney cancers start when something goes wrong in the genes in the kidney. No one can say for certain why that happens. Several factors can raise your chances of getting the disease, like: Smoking. Being very overweight. Taking a lot of pain medicine, like aspirin, ibuprofen, or acetaminophen, for a long time. Exposure to certain dyes, asbestos, cadmium (a metal), herbicides, and solvents. Some inherited conditions, especially von Hippel-Lindau disease. How Is Renal Cell Carcinoma Diagnosed? If your doctor suspects that you may have RCC, he will ask about your personal and family history. He will then do a physical exam. Findings that can indicate RCC include swelling or lumps in the abdomen, or, in men, enlarged veins in the scrotal sac. If RCC is suspected, your doctor will order a number of tests including: A complete blood count. A CT scan. Abdominal and kidney ultrasounds. Urine examination. A biopsy. Treatments for Renal Cell Carcinoma. There are five kinds of standard treatments for RCC. One or more may be used to treat your cancer. Surgery: Surgery can include different types of procedures. During a partial nephrectomy, part of the kidney is removed. During a nephrectomy, the entire kidney may be removed. Depending on how far the disease has spread, more extensive surgery may be needed to remove surrounding tissue, lymph nodes, and your adrenal gland. This is a radical nephrectomy. If both kidneys are removed, a dialysis or a transplant is necessary. Radiation: Radiation therapy involves using high-energy X-rays to kill cancer cells. The radiation can be given externally by a machine, or placed internally using seeds or wires. Chemotherapy: Chemotherapy uses drugs to kill cancer cells. It can be given orally or intravenously, depending on what medication is chosen. This allows the drugs to go through the bloodstream and reach cancer cells that may have spread to other parts of the body. Biologic therapy: Biologic therapy, also called immunotherapy, works with your immune system to attack the cancer. Enzymes or substances made by the body are used to defend your body against the cancer. Targeted therapy: Targeted therapy is a newer kind of cancer therapy. Drugs are used to attack certain cancer cells without damaging healthy cells. Some drugs work on blood vessels to prevent blood flow to the tumor, “starving” and shrinking it. Clinical trials: Clinical trials are another option for some patients with RCC. Clinical trials test new treatments to see if they are effective in treating the disease. During the trial you will be closely monitored, and you can leave the trial at any time. Talk with your treatment team to see if a clinical trial is a viable option for you. Like and share this video. Don't forget to Subscribe my channel for health updates.
Views: 5232 Health Tips
Renal Cell Carcinoma for USMLE
Renal Cell Carcinoma Anatomy, Epidemiology, Etiology, Clinical Signs and Symptoms, Treatment and Management. Handwritten, full lecture for medical students taking USMLE. Renal Cell Carcinomas make up 90-95% of kidney neoplasms. ETIOLOGY of Renal Cell Carcinoma Smoking is the largest risk factor. Obesity and Hyppertension is a known risk factor for Renal Cell Carcinoma in Women. Occupational Exposure such as Trichloroethylene, Benzine, Herbicides, Vinyl Chloride. Drugs associated with Renal Cell Carcinoma (phenacitin). Long term dialysis increases the risk of cystic Diseases which increase risk of renal cell carcinoma. Von Hipel Lindau - Loss of 3p increases HIF which increases angiogenesis. Also increase risk of pheochromocytoma, pancreatic cysts/islet cell tumors, retinal angiomas, CNS hemangioblastomas. Hereditary Papillary Renal Carcinoma - MET Gene mutation of tyrosine kinase domain and will have bilateral multifocal papillary renal cell carcinoma. Burt-Hogg-Dube Syndrome - Bilateral Multifocal oncocytoma which has a better prognosis. Also may cause pulmonary and colonic tumors. CLINICAL SIGNS AND SYMPTOMS of Renal Cell Carcinoma. The three most common presenting signs and symptoms is flank pain, hematuria, flank mass. A large percentage of patients may be asymptomatic. Patients with renal cell carcinoma may also have wieght loss, varicocele, malaise, fever. Paraneoplastic syndromes are very common in renal cell carcinoma. Increase EPO may lead to polycythemia, Renin production may lead to hypetension. Finally may also have hypercalcemia, polyneuropathy. Shauffer Syndrome - Non-metastatic Hepatic Dysfunction and therefore it is important to monitor liver function, even if no metastasis has occurred. Metastasis to Lungs (45%), Soft tissue and Liver. Work Up for Renal Cell carcinoma Labs - Urinalysis, CBC, Electrolytes, Renal Profile, LFT (AST/ALT) and Serum Calcium. Imaging - CT scan is the imaging of choice and can identify the tumor and rule out cystic mass. Also allows visualtion of Lymph nodes, Renal Vein, IVC and helps rule out angiolipoma. For staging abdominal ;pelvic CT with or without contrast. Chest X-ray and Brain MRI. Histology Clear Cell Carcinoma - 75%, lipid/glycogen Chromphilic - Bilateral mulftifocal Chromophobic - Large polygonal Cells Oncocytoma - Rarely metastasize Collecting Tubules STAGING OF Renal Cell Carcinoma Stage 1 - Within the kidney and less than 7cm. Stage 2 - Within the kidney and greater than 7cm. Stage 3 - Invasion Renal Vein and Inferior Vena Cava or Adrenal Gland, but does not invade Gerota's Fascia Stage 4 - Extends below Gerota's Fascia, invade nearby lymph nodes and metastasis to organs. MANAGEMENT of Renal Cell Carcinoma Surgical Partial nephrectomy for stage 1 and sometimes stage 2 Radical Nephrectomy - remove complete removal of Gerota's fascia, Removal of kidney with adrenal gland, dissect enlarge lymph nodes. Palliative Nephrectomy - remove kidney to alleviate pain, polycythemia and hypertension. Adjuvant Treatment for Renal Cell Carcinoma Biologic Response Mediators - IL2 (activates T Cell and NK), IFN Molecular Targeting - Suritinib, Bevacizumab, Dazopomib, Temsirolimu, Sorafenib. Chemotherapy - 5 floururacil, Vinblastine, Paclitaxel, Caboplatin, Ifosfamide, Gemcitabine. Radiation - Renal Cell Carcinoma is not sensitive to radiation but the brain metastasize are sensitive. Renal Artery Embolization inject ethanol or gelatin sponge pledgets in artery feeding tumor to help kill off the tumor. Also done palliative for non-surgical patient.
Views: 18225 the study spot
Treating Advanced Renal-Cell Carcinoma
Approximately 75% of patients with advanced renal-cell carcinoma have an intermediate or poor prognosis, with a low rate of response to standard treatment with sunitinib and a high rate of toxic effects. Full trial results: http://nej.md/2GaYWq9 Watch more Quick Take videos: http://nej.md/quick-take
Views: 1656 NEJMvideo
Renal Cell Carcinoma: Past, Present, and Future
Information presented in this presentation is designed to increase knowledge about renal cell carcinoma (RCC). Information focuses on risk factors associated with RCC, the standard treatments for both localized and metastatic disease, and the future for RCC treatment. Learning Outcomes: • State the risk factors for kidney cancer, including the genetic syndromes associated with renal cell carcinoma. • Discuss the current status of adjuvant treatment for high-risk localized kidney cancer. • State the standard first- and second-line systemic therapies for metastatic kidney cancer. This lecture was presented as part of the Medical and Surgical Oncology Lecture Series.
Views: 667 UNC Cancer Network
Histopathology Kidney--Renal cell carcinoma
Histopathology Kidney--Renal cell carcinoma
Views: 18867 WashingtonDeceit
Histopathology Kidney-- Renal cell carcinoma
Histopathology Kidney-- Renal cell carcinoma
Views: 12477 WashingtonDeceit
Renal Cell Cancer
Renal cell cancer is the most lethal of urologic cancers Bone metastases in patients with renal cell cancer (RCC) are associated with a high risk of skeletal complications. About 40% of patients with RCC develop bone metastases. RCC is the fourth most common metastatic tumor of the spine and the most common cancer to present as a neurologic deficit secondary to an undetected primary malignancy. Chemotherapy and hormone therapy are ineffective, making radiation and surgery the mainstays of treatment. Failure to respond to or relapse after radiotherapy is common (American Journal of Neuroradiology 22:997-1003 (5 2001) The median survival time with distant metastatic RCC is around 6 months, and few cases survive beyond 2 years. The incidence of spontaneous regression of metastatic renal cell cancer is thought to be less than 1% of all cases. It is reported that complete regression is even rarer than partial regression
Views: 302 Prashant Sawant
Stage 4 Renal Cell Carcinoma Metastasis, Survival Rates, and Treatment
Stage 4 Renal Cell Carcinoma Metastasis, Survival Rates, and Treatment. What Is Renal Cell Carcinoma?. Renal cell carcinoma (RCC), additionally called renal cell tumor or renal cell adenocarcinoma, is a typical kind of kidney growth. Around 90 percent of all kidney growths are renal cell carcinomas. RCC normally starts as a tumor developing in one of your kidney. It can likewise create in both kidneys. The ailment is more typical in men than ladies. How Can It Spread?. On the off chance that a malignant tumor is found in one of your kidneys, the typical treatment is to evacuate part or the majority of the influenced kidney surgically. On the off chance that the tumor is abandoned, it's more probable that the growth will spread to either your lymph hubs or different organs. The spread of growth is called metastasis. On account of RCC, the tumor can attack a huge vein driving out of the kidney. It can likewise spread to the lymph framework and different organs. The lungs are particularly helpless. TMN Staging and the Stages of Kidney Cancer. Kidney malignancy is depicted in stages created by the American Joint Committee on Cancer. The framework is also called the TMN framework. *The "T" alludes to the tumor. Specialists appoint a "T" with a number from one to three, in view of the size and development of the tumor. *An "N" depicts whether the disease has spread to a hub in the lymph framework. *The "M" implies the tumor has metastasized. Specialists likewise dole out RCC a phase in view of the measure of the tumor and the spread of the growth. There are four phases: *Stages 1 and 2 portray malignancies in which the tumor is still in the kidney. Stage 2 implies that the tumor is developing and is bigger than seven centimeters over. *Stages 3 and 4 mean the malignancy has spread either into a noteworthy vein, to lymph hubs, or to different organs. *Stage 4 is the most developed type of the malady. Stage 4 implies that the disease has metastasized to the lymph framework or different organs. Since the adrenal organ is appended to the kidney, the malignancy regularly spreads there first. Stage 4 kidney disease likewise implies that the malignancy may have spread into more than one lymph hub close to the kidney or somewhere else in the body. What's the Outlook?. Five-year survival rates for RCC depend on the level of patients who inhabit minimum five years with the malady after it's been analyzed. The American Cancer Society reports the accompanying five-year survival rates, as indicated by organize: *stage 1: 81 percent. *stage 2: 74 percent. *stage 3: 53 percent. *stage 4: 8 percent. What Are the Treatment Options?. The sort of treatment you get to a great extent relies upon the phase of your tumor. Stage 1 RCC might be treated with surgery. Be that as it may, when the disease has progressed to arrange 4, surgery is frequently impossible. In the event that the tumor and metastasis can be secluded, surgical expulsion of the malignant tissue may at present be conceivable. On the off chance that the malignancy has spread to the lungs, incomplete lung expulsion may dispose of the tumor. On the off chance that you have organize 4 RCC, your specialist will think about your general wellbeing to decide your qualification for significant surgery. In the event that surgery isn't a practical choice to treat arrange 4 RCC, different treatments may help. One approach is embolization, which is the hindering of blood stream to malignancy cells. In any case, there's a hazard that the substance that hinders the blood stream will likewise meddle with flow to solid cells. Another alternative is radiation treatment. This treatment utilizes high-vitality radiation to target growth cells. In any case, it's not typically effective when the malignancy has spread to numerous areas. Diagram: The most ideal approach to beat organize 4 RCC is to forcefully treat the disease before it gets the opportunity to arrange 4. In case you're in arrange 4 RCC, recall that distributed survival rates are midpoints. The key is to take after your specialist's recommendation, go to your arrangements, and take your medicines. Likewise, make a point to roll out whatever way of life improvements your specialist recommends. All Photos Licensed Under CC Source : www.pexels.com www.pixabay.com www.commons.wikimedia.org
Views: 5159 Beauty & Health Tips
Clear Cell and Chromophobe Renal Cell Carcinoma
Histologic featues and facts about clear cell and chromophobe renal cell carcinomas
Views: 5773 UAMS Pathophysiology
Renal Cell Carcinoma Prognosis Life Expectancy and Survival Rates
Renal Cell Carcinoma Prognosis Life Expectancy and Survival Rates. What is renal cell carcinoma?. Kidney disease happens when growth cells shape in the kidneys. More than 90 percent of kidney growths are renal cell carcinomas (RCC), which begin in the tubules of the kidneys. Tubules are modest tubes in the kidneys that assistance channel squander items from the blood keeping in mind the end goal to make pee. The rest of the 10 percent of kidney tumors begin in the renal pelvis in the focal point of the kidney, which is the place pee gathers. In the United States, kidney tumor is the seventh most basic growth in men and the ninth most normal disease in ladies, as per the Cleveland Clinic. What builds your hazard?. Hazard factors for creating renal cell carcinoma include: *smoking. *hypertension. *obesity. hepatitis C. What are the main side effects?. One of the primary manifestations of kidney malignancy is the presence of blood in the pee. Furthermore, infrequently a protuberance can be felt in the mid-region. How is it analyzed?. To analyze kidney tumor, a specialist will play out a physical exam and request imaging tests, for example, *ultrasound. *CT examine. *MRI. Your specialist will arrange a urinalysis and other lab work on the off chance that they speculate malignancy or other kidney malady. On the off chance that the lab and imaging tests uncover a suspicious mass, your specialist will complete a biopsy to check for harmful cells. Beginning periods of kidney tumor. When kidney tumor is affirmed, your therapeutic group will decide the phase of the growth. The stage depends on how much or how little the malignancy has spread. *Stage 1 implies the growth is just in the kidney, and that the tumor is 7 centimeters in length or littler. *Stage 2 implies the growth is as yet contained to the kidney, however the tumor is bigger than 7 centimeters. At the point when kidney tumor metastasizes. Stages 3 and 4 show that the tumor has metastasized, or spread to different parts of the body. Kidney disease spreads through blood, lymph hubs, or by coordinate augmentation of the first carcinogenic tumor into adjacent tissue or structures. *Stage 3 implies the tumor is additionally present in a lymph hub close to the kidney, or in a principle kidney vein or greasy tissue around the kidney. *Stage 4 implies the malignancy has spread to another organ, or removed lymph hubs. Treatment alternatives. Treatment for kidney malignancy relies upon the phase of the tumor. In the event that the tumor is little and the patient is qualified for surgery, an incomplete nephrectomy might be conceivable. This task saves the kidney, yet evacuates the tumor and a portion of the encompassing tissue. A full nephrectomy, in which a whole influenced kidney is evacuated, might be vital in further developed cases. Now and again, where surgery isn't a choice, cryoablation might be an answer if the tumor is strong and in a contained region. Cryoablation is a methodology that includes the solidifying of tumor cells. Empowering prescription advancements. Prescription treatment is regularly utilized if the malignancy has spread. These medications help support the body's safe framework. There additionally have been empowering advancements with drugs that objective kidney growth cells, as indicated by the Cleveland Clinic. As per the American Cancer Society, there are seven focused on treatment medicines for kidney disease. Directed treatments are drugs that objective particular receptors or atoms along the disease cell development pathways that moderate or end malignancy development. Components influencing viewpoint. All Photos Licensed Under CC Source : www.pexels.com www.pixabay.com www.commons.wikimedia.org
Views: 5990 Beauty & Health Tips
How to treat and cure  Kidney cancer renal cell cancer
This video has how to treat Kidney cancer (renal cell cancer)-How to treat and cure Kidney cancer (renal cell cancer)
Views: 4370 Shelby Lopez
New Drug Proves Effective For Renal Cell Cancer Patients
New research has identified a treatment for metastatic renal cell cancer that is more effective and better tolerated in the recovery of those patients. According to UPI online, the new drug known as nivolumab combined with ipilimumab revealed manageable safety, antitumor activity and favorable responses garnering potential long-term benefits across the board in patients with metastatic renal cell cancer. Annually there are 338,000 patients diagnosed with mRCC. The study, was published in the July edition of the Journal of Clinical Oncology. https://www.upi.com/Health_News/2017/07/26/Drug-combination-more-effective-in-metastatic-renal-cell-cancer/6101501081337/ http://www.wochit.com This video was produced by YT Wochit News using http://wochit.com
Views: 317 Wochit News
Outcomes for patients with locally advanced renal cell carcinoma Christopher G. Wood, M.D., UT
Outcomes for patients with locally advanced renal cell carcinoma Christopher G. Wood, M.D., UT MD Anderson Cancer Center
Views: 3832 Kidney Cancer
Kidney Cancer Survival Rate
Click on http://stayhealthyvideos.com/kidneydisease to learn more about kidney health in general. Click on http://stayhealthyvideos.com/kidneydiet to get detailed information about a kidney healthy diet. Transcript: Kidney Cancer Survival Rate The kidney cancer survival rate depends on a number of different factors related to both the individual patient and to the kidney cancer itself. In estimating a kidney cancer survival rate, medical researchers must consider a general range of variables, including the type of cancer, the stage, the grade, and the location. There are also influential variables that are specific to each patient, including age, general health, and individual response to treatment. This said, medical researchers have been able to come up with general kidney cancer survival rate numbers. The statistics in this article focus on the most common type of cancer of the kidney, which is known as renal cell carcinoma. Calculations for the kidney cancer survival rate are expressed as a percentage of patients with a certain type of kidney cancer which has reached a certain stage Statistically, patients with kidney cancer of a certain type at a certain stage may generally expect to survive for at least a certain period of time after being diagnosed. Of course, as is the case with most studies, the kidney cancer survival rate is based on analysis of a large number of patients. It's impossible to accurately predict outcomes for every individual. The standard survival rate used for cancer of the kidney (and many other diseases) is a five-year interval. In other words, the percentage of kidney cancer patients will still be alive five years after their diagnosis. The percentage does not consider whether the patient still has kidney cancer, or whether he or she is completely in remission or free of symptoms. It only reports whether or not the patient is still alive. There are different ways to calculate kidney cancer statistics. The numbers below are based on a measure of the survival of kidney cancer patients in comparison to the general population. The time period in this study was 1995-2001. The overall kidney cancer survival rate for this period was 64.6 percent. Broken down by race and gender, the numbers were: 64.7 percent for Caucasian men 64.5 percent for Caucasian women 61.8 percent for African American men 65.9 percent for African American women. It's also important to consider how far the disease has progressed in calculating a survival rate. The degree of progress is known as the kidney cancer stage. 53 percent of kidney cancer cases are diagnosed while the cancer can only be found in the kidney. It has not spread to other parts of the body (metastasis). 20 percent of cases are discovered after cancer has spread to lymph nodes or directly beyond the primary area (known as the regional stage). 22 percent after has already metastasized in another organ or area of the body (the distant stage). Staging information was unknown for the remaining percentage. As you would expect, a higher percentage of patients whose kidney cancer was diagnosed in the earlier stages typically survived the longest. Other kidney cancer statistics include the following: 90 percent reached the five year survival mark when the cancer was localized in the kidney. 60 percent for regional 9.7 percent for distant 32.2 percent for unknown or undiagnosed stages.
Views: 7674 WS Westwood
Kurt Mayer Renal Cancer Story
Kurt Mayer Cancer Story
Views: 1567 Megan Johnson
Easy way to remember TNM Staging of Renal Cell Carcinoma with Visual mnemonic
You will never forget TNM staging of the kidney with this method.
Views: 1133 MED Tutorials
Treating Advanced Renal Cell Carcinoma (RCC)
Take the kidney out, it’s all gone, you live happily ever after, to, yeah, this didn’t work so well. And it was very disappointing, of course. Nothing anybody can do about it. Move on from there. What’s next? ~Bruce Gowin, Advanced RCC Patient Immunotherapy for treatment of cancers has been around for a very long time. We actually used to use immunotherapy a lot to treat advanced kidney cancers until the targeted therapy era came, where we used pills to treat the kidney cancer instead. But now, there has been a re-emergence of immuno-onocology agents, next generation checkpoint inhibitors that actually rev up a patient’s immune system, so that the immune system attacks their own tumor. And, they’ve been able to extend survival, improve quality of life, and really revolutionize how we treat kidney cancer today. ~ Daniel Heng MD MPH FRCPC Clinical Associate Professor, University of Calgary Chair, Southern Alberta GU Tumor Group Staff Medical Oncologist, Tom Baker Cancer Center
Views: 147 editextreme
Papillary Kidney Cancer Clinical Trials
The world's largest, most respected, and fully accredited kidney cancer charity presents information of interest to patients seeking a clinical trial for treatment of papillary kidney cancer. Interested in learning more about how to join a clinical trial? See: http://emergingmed.com/partners/kca/
Views: 1573 Kidney Cancer
Renal Cell Carcinoma Patient Testimonial at Cleveland Clinic
Learn more about Stewart Brown, a Cleveland Clinic patient who had successful minimally invasive kidney cancer surgery for renal cell carcinoma performed by Jihad Kaouk, MD, Director of Laparoscopic and Robotic Surgery at the Glickman Urological and Kidney Institute. Learn more about kidney cancer treatment at Cleveland Clinic by visiting http://www.clevelandclinic.org/kidneycancerguide. Stay connected to Cleveland Clinic: ➨ Visit Cleveland Clinic: http://bit.ly/XlxDfr ➨ Visit Health Hub from Cleveland Clinic: http://bit.ly/VBQ3nW ➨ Subscribe to our YouTube Channel: http://bit.ly/W0bJ0y ➨ Like Cleveland Clinic on Facebook: http://on.fb.me/WMFkul ➨ Follow Cleveland Clinic on Twitter: http://bit.ly/Uua1Gs ➨ Follow Cleveland Clinic on Pinterest: http://bit.ly/11QqS3A
Views: 8887 Cleveland Clinic
Papillary renal cell carcinoma
Patient with hematuria. MR images demonstrate a T2 hypointense mass arising from the kidney. While enhancement is difficult to perceive on the standard post-gadolinium images, the subtraction images demonstrate subtle nodular enhancement along the posterior margin of the mass, increasing over the venous and delayed images. This was found to be a papillary renal cell carcinoma.
Views: 1097 CTisus
Bone and Brain Metastases in Renal Cell Carcinoma
The panelists, Daniel Heng, MD, MPH, FRCPC; Paul Nathan, MBBS, PhD, FRCP; Nizar Tannir, MD, FACP; Susanne Osanto, MD, PhD; and Carlos H. Barrios, MD, share practice experiences regarding the management of bone and brain metastases in individuals with renal cell carcinoma (RCC).
Views: 464 OncLiveTV
Metastatic Kidney Cancer Survivors – Peggy and Thomas
This is a story of Peggy and Thomas, metastatic kidney cancer patients, whose lives changed with this traumatic diagnosis.
New Treatment Paradigm for Advanced Renal Cell Carcinoma
MSKCC genitourinary cancer expert Robert Motzer discusses new treatment options for patients with advanced renal cell carcinoma.
Renal Cell Kidney Cancer with Lung and Bone Metastases
After one year of Issels Treatment Carol Gayle in her own words: March 17, 2008: "I've been on the Issels Program for a year. Every three months I have my CT scans and bone scans and every time I've gone since a year ago they have been improved. My tumors have decreased in size every time, there's no new cancer showing and I continue to be on the Issels Treatment and it's done very well for me." In March 2009 Carol reports to be in very good condition. The Issels Treatment is a comprehensive immunotherapy program that integrates the most effective state-of-the-art technologies, such as advanced cancer vaccines, and other safe and scientifically validated therapies. For more information on the Issels Treatment, please visit http://www.issels.com or call 1.888.447.7357.
Views: 9572 Issels Immunotherapy
Take Out That Kidney! - My Battle With Stage IV Renal Cell Cancer
In June, 2017, I collapsed at the park and was taken to a local hospital where specialists found a cancerous tumor on my kidney. The stage IV cancer has also spread to my lungs and spine. Medical professionals are currently using every possible option to treat this terrible disease. At this time, I am scheduled to undergo radical nephrectomy (complete removal), of my right kidney. I will fight with everything I have to beat this thing. Thank you for the love and support and to others who are facing a similar battle..may you be blessed in your fight as well. Let's kick cancer's ass! - Clay - https://www.gofundme.com/medical-fund-for-clay-mullins
Views: 615 Living With Cancer
Potential new treatments in renal cell carcinoma
Toni Choueiri, MD, from the Dana Faber Cancer Institute, Boston, MA, discusses three exciting trials in renal cell carcinoma (RCC) presented at the European Society for Medical Oncology (ESMO) 2017 in Madrid, Spain. There was an update on the CABOSUN trial (NCT01835158) which compared caboxantinib and sunitinib. This study has been reviewed recently by an independent reviewer, with cabozantinib still found to be superior to sunitinib, with an even better hazard ratio. The KEYNOTE-564 trial (NCT03142334) is currently recruiting patients to investigate the efficacy of pembrolizumab versus placebo as adjuvant treatment in patients with high risk RCC that have had a nephrectomy. This will hopefully show some promising results. The third trial was investigated the efficacy of savolitinib in papillary non-clear cell RCC patients with MET mutations (NCT030911920). The primary endpoint of this study will be progression free survival, and will hopefully provide an alternative to the current standard of care for these patients.
Views: 137 VJOncology
Recent Advances in Renal Cell Carcinoma
Dr. Erik P. Castle, MD, discusses the most recent advances in renal cell carcinoma treatment, especially in regards to individualized medicine, immunotherapy, robotics, partial nephrectomy, and other surgeries.
Radiation Therapy in Renal Cell Carcinoma
In this segment, Saby George, MD, explains the forms of radiation therapy used in renal cell carcinoma.
Views: 334 OncLiveTV
ASCO GU: Highlights on Renal Cell Cancer: IMmotion151 and other combination studies
Reporting from ASCO GU 2018, Bernard Escudier states that the results from studies presented are likely to be practice changing for the treatment of patients with renal cell cancer (RCC), regarding first-line options and patients' selection. In untreated metastatic RCC, the IMmotion151 trial showed a 3 months increase in progression-free survival (PFS) with atezolizumab/bevacizumab versus sunitinib in PD-L1 positive patients according to the investigator's analysis. In this trial, the independent review analysis of data didn't confirm the statistically significant difference in PFS, which is important as every drug approval in RCC has been based on results from independent reviews. In this study, there is a positive trend in term of overall survival and if confirmed, the protocol should become a standard of care in RCC. The update on the phase Ib study on safety and efficacy of axitinib combined with pembrolizumab in advanced RCC showed a very impressive response rate of 73%, a complete remission rate of 7% with a relatively good safety profile. Results from a phase Ib/II French study with nivolumab combined with tivozanib also showed a very high response rate of 64%. In conclusion, Bernard Escudier says that after Nivo-Ipi combination presented at ESMO 2017, with combinations of VGFR and PD-1 or PD-L1 blocking agents presented at ASCO GU 2018, we are certainly moving from monotherapy to combination RCC treatment. Next question to address will be patients selection to know which profile will benefit the most from which combination. We had some indications that PD-L1 should be tested and in case of positive status patients may benefit more from the Nivo-Ipi combination, and if PD-L1 negative may have a better response with the combination of IO plus VEGF targeted agents. Sunitinib and pazopanib which have been the reference in the last 10 years will most likely become later line treatment. Produced by the European Society for Medical Oncology http://www.esmo.org
Renal Cell Carcinoma - Overview
This video provides a look at RCC, including epidemiology, the different types, surgical options etc.
Views: 12398 Jas Gill
Pazopanib and Sunitinib in Renal Cell Carcinoma
Robert Figlin, MD, and Nizar Tannir, MD, FACP, examine data comparing tyrosine kinase inhibitors (TKIs), pazopanib with sunitinib, in renal cell carcinoma (RCC).
Views: 1827 OncLiveTV
Older patients benefit from lower doses of sunitinib in renal cell carcinoma
Visit http://www.ecancer.org for more. "We must dispel this concept of ageism," Dr Kanesvaran (National Cancer Centre Singapore, Singapore) tells ecancertv at SIOG 2014. He discusses his study on sunitinib in metastatic renal cell carcinoma, which found that patients benefit from a lower dose. Older patients may particularly benefit from starting treatment at lowered doses.
Views: 77 ecancer
Kidney Cancer and Immunotherapy: Tatiana Baker's Story
Tatiana Baker of Boynton Beach, Florida was diagnosed with advanced kidney cancer in the summer of 2014. After running out of treatment options in just a few months, she traveled to MedStar Georgetown where she enrolled in the IMmotion 150 study, a phase II clinical trial of the immunotherapy atezolizumab through Georgetown University’s Lombardi Comprehensive Cancer Center. Atezolizumab was approved for bladder cancer in May 2016. Watch to see how Tatiana became cancer free. For more information call 1-888-666-3432 or go to http://www.medstargeorgetowncancer.org
Utilizing Frontline Bevacizumab in Metastatic Renal Cell Carcinoma
In this segment, panelists discuss the utilization of bevacizumab as a frontline therapy for patients with metastatic renal cell carcinoma (mRCC). This discussion includes information on the phase IIIb INTORACT trial and the investigation of bevacizumab as a monotherapy. To view more from this discussion, visit http://www.onclive.com/peer-exchange/rcc-advances
Views: 188 OncLiveTV
Immunotherapy in Renal Cell Carcinoma
In this segment, Sumanta Kumar Pal, MD, discusses PD-1 blockade in the management of renal cell carcinoma.
Views: 806 OncLiveTV
Immunotherapy for Metastatic Kidney Cancer Shows Increased Survival
The immune checkpoint inhibitor Opdivo (nivolumab) has been shown to increase survival for patients with metastatic clear cell kidney cancer (also called renal cell carcinoma, or RCC).
Dr Laurence Albiges discusses the management of papillary renal cell carcinoma (pRCC)
At the Thirteenth International Kidney Cancer Symposium, Dr Laurence Albiges (Gustave Roussy, France) provides an overview of papillary renal cell carcinoma (pRCC) and management options for these patients. pRCC comprises 10–15% of renal cell carcinoma and specific therapies are not available. There are two clinically distinct types of pRCC. The more common Type 1 pRCC is associated with a mutation in the MET gene.
Dr. Motzer on Sunitinib Versus Pazopanib in Renal Cell Carcinoma
Robert J. Motzer, MD, attending physician, genitourinary oncology service, Memorial Sloan-Kettering Cancer Center, discusses the use of pazopanib compared with sunitinib as first-line therapy for patients with renal cell carcinoma. For more resources and information regarding targeted therapies in cancer: http://targetedhc.com/
Views: 941 Targeted Oncology
Kidney Cancer
Click on http://stayhealthyvideos.com/kidneydisease to learn more about kidney health in general. Click on http://stayhealthyvideos.com/kidneydiet to get detailed information about a kidney healthy diet. Transcript: Kidney Cancer - What Is Kidney Cancer? Kidney cancer causes about 12,000 deaths each year in the United States alone. It tends to occur in adults after age 50 and about twice as many men get kidney cancer as women. Approximately 30,000 patients a year get a kidney cancer diagnosis from their doctor, according to statistics from The American Cancer Society. Factors that influence a kidney cancer prognosis include, type, grade, stage, location, patient's age, general health, and individual response to treatment. A doctor considering a patient's kidney cancer prognosis will also factor in the most recent survival rate statistics. However, every prognosis is only a doctor's best guess. It's impossible to accurately predict outcomes for every individual patient. When evaluating outcomes, doctors generally look at statistics for the five-year survival rate. The five-year rate is the percentage of people who are alive five years after being diagnosed. There are several types of kidney cancer. The most common type is called renal cell cancer, or renal cell carcinoma. It occurs in the area of the kidneys that filter blood and produce urine. Another type of cancer of the kidney, known as transitional cell carcinoma, is a tumor that grows in the area of the kidney where urine collects. The most common symptom of kidney cancer in adults is the appearance of blood in the urine. Renal cell carcinoma develops about twice as often in smokers as in nonsmokers. It's estimated that anyone who stops smoking will reduce their chance of getting renal cancer by fifty percent. Eliminating smoking would probably cut renal cell carcinoma by one third. Kidney cancer tends to appear in different forms in children and adults. The main type of kidney cancer in children is Wilms tumor, which begins to develop while the fetus is still in the womb. Wilms' tumor accounts for about six percent of childhood cancer cases. Wilms tumor may be caused by certain congenital defects. The tumor may be quite large by the time it's diagnosed, which is typically around age three. In some cases, blood in the urine is a symptom, and there can also be pain and discomfort in the abdominal area. There's an increased incidence of wilms tumor among siblings and twins. As happens with many other types of cancer, kidney cancer cells can spread through the lymphatic system and grow elsewhere the body. When this occurs, it is called metastatic kidney cancer. The new tumor is called the metastatic tumor. In other words, if cells from cancer of the kidney break away and spread to organs, like the liver, the cancer is still considered to be a form of kidney cancer, not liver cancer. As with most types of cancer, the sooner it is detected, the higher the survival rate. Tumors often respond well to treatment if they are diagnosed early. Treatment options include surgery, hormone therapy, biological therapy, embolization, chemotherapy and radiation therapy.
Views: 3859 WS Westwood
What Causes Kidney Cancer?
Transcript: What Causes Kidney Cancer? Kidney cancer causes are unclear. At this point medical researchers have only been able to learn that kidney cancer begins much in the same way as other cancers begin: through DNA mutations. These mutations program the cells to grow and divide abnormally, forming a tumor. The cells can also spread to other parts of the body (a process known as metastasis). A type of kidney cancer known as renal cell carcinoma is the most common variety in adults. A number of others are less common, including transitional cell carcinoma, which can begin in the kidneys but can affect the ureters. A condition known as Wilms tumor is the most common cause of kidney cancer in children. While precise causes have been difficult to isolate, researchers have been able to discover that there are certain risk factors for kidney cancer that seem to make development more likely. It's probably not a coincidence that these possible kidney cancer causes are similar to causes that are often connected to other types of cancer. As you get older, especially past age 65, your odds of getting kidney cancer increase. Smokers have a higher chance of getting kidney cancer than nonsmokers do. If you quit, your chances go down. People who are grossly overweight or morbidly obese are more likely to get kidney cancer. High blood pressure increases your risk of kidney cancer. High blood pressure and diabetes are both extremely dangerous for those with kidney disease, but the exact connection between hypertension and kidney cancer is unclear. Kidney failure also appears to be one of the causes of kidney cancer. Individuals who receive kidney dialysis treatments for renal insufficiency or chronic kidney failure develop kidney cancer at a higher rate than those who don't. Hereditary factors may also play a role. People with an inherited disorder known as Von Hippel-Lindau disease seem to be prone to developing several kinds of tumors, including kidney cancer. There's also a condition known as hereditary papillary renal cell carcinoma that appears to be one of the kidney cancer causes. Gender may be important. Statistically, more men develop kidney cancer than women. Certain non-medical factors may helps cause kidney cancer. Environmental factors, like certain kinds of chemicals in your workplace may put you in a higher risk group. Research seems to indicate that people who work around asbestos and cadmium have higher kidney cancer rates than the normal population. There are a number of kidney tests available to detect kidney cancer and other types of kidney problems. One method employs ultrasound to generate images of the kidneys. CT and MRI scans are other popular diagnostic tools. Kidney cancer causes few symptoms until it progresses to a later stage. When symptoms of kidney cancer begin to appear, they're likely to include a dark, cloudy, or even red-tinged urine stream (indicating blood in urine), back pain in the flank region, just below the ribs, unexplained weight loss, fatigue and difficulty concentrating fever, vomiting and nausea. If you have any of these symptoms, it is important to see your medical professional as soon as you can. Your doctor will run kidney tests and use other diagnostic tools to see if you have kidney problems. Once again, the sooner kidney cancer is detected, the more likely it is there will be a happy outcome. The incidence of kidney cancer seems to be increasing. More than 50,000 individuals are diagnosed with kidney cancer each year and this number is growing, though it isn't clear why. The death rate for kidney cancer is approximately 12,000 persons annually in the United States.
Views: 30449 WS Westwood
Renal Cell Cancer Health Byte
Renal Cell cancer (kidney cancer) is found in the kidney and can occur in both adults and children, but most commonly in adults. In this video learn more about this cancer and its various forms, its symptoms, treatments, and preventative techniques.
[Interview with Author] Prognosis in Chromophobe RCC to the Chromophobe Tumor Grading (CTG) System
KJU - Video Interview with Author - 2014-04 Title: Relating Prognosis in Chromophobe Renal Cell Carcinoma to the Chromophobe Tumor Grading (CTG) System Authors: Elizabeth P Weinzierl, Alan E Thong, Jesse K McKenney, Seung Hyun Jeon, Benjamin I Chung Citation: Korean J Urol 2014;55:239-244 Original article: http://www.kjurology.org/Synapse/Data/PDFData/0020KJU/kju-55-239.pdf
Views: 507 KJUrology
Renal Cell cancer: Small Renal Mass: Surveillance vs. Surgery/Ablation
FOIU 2014 Symposium Session Topic: Active Surveillance in Uro Oncology: Rationale, Risks and Outcomes David Goldfarb, USA
Views: 701 FOIUSymposium
Treatment Options in Renal Cell Carcinoma
The panelists, Robert Figlin, MD; Sandy Srinivas, MD; and Martin Voss, MD, comment on their thought processes when determining which treatment to use in renal cell carcinoma (RCC).
Views: 1318 OncLiveTV
Dr. Lara on the Role of Sunitinib for Renal Cell Carcinoma
Primo N. Lara, MD, associate director for translational research, UC Davis Comprehensive Cancer Center, discusses the role of sunitinib (Sutent) for patients with renal cell carcinoma (RCC).
Views: 67 OncLiveTV